Differentiating effects of the glucagon-like peptide-1 analogue exendin-4 in a human neuronal cell model

Glucagon-like peptide-1 (GLP-1) is an insulinotropic peptide with neurotrophic properties, as assessed in animal cell models. Exendin-4, a GLP-1 analogue, has been recently approved for the treatment of type 2 diabetes mellitus. The aim of this study was to morphologically, structurally, and functio...

Full description

Saved in:
Bibliographic Details
Published inCellular and molecular life sciences : CMLS Vol. 67; no. 21; pp. 3711 - 3723
Main Authors Luciani, Paola, Deledda, Cristiana, Benvenuti, Susanna, Cellai, Ilaria, Squecco, Roberta, Monici, Monica, Cialdai, Francesca, Luciani, Giorgia, Danza, Giovanna, Di Stefano, Chiara, Francini, Fabio, Peri, Alessandro
Format Journal Article
LanguageEnglish
Published Basel Basel : SP Birkhäuser Verlag Basel 01.11.2010
SP Birkhäuser Verlag Basel
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Glucagon-like peptide-1 (GLP-1) is an insulinotropic peptide with neurotrophic properties, as assessed in animal cell models. Exendin-4, a GLP-1 analogue, has been recently approved for the treatment of type 2 diabetes mellitus. The aim of this study was to morphologically, structurally, and functionally characterize the differentiating actions of exendin-4 using a human neuronal cell model (i.e., SH-SY5Y cells). We found that exendin-4 increased the number of neurites paralleled by dramatic changes in intracellular actin and tubulin distribution. Electrophysiological analyses showed an increase in cell membrane surface and in stretch-activated-channels sensitivity, an increased conductance of Na⁺ channels and amplitude of Ca⁺⁺ currents (T- and L-type), typical of a more mature neuronal phenotype. To our knowledge, this is the first demonstration that exendin-4 promotes neuronal differentiation in human cells. Noteworthy, our data support the claimed favorable role of exendin-4 against diabetic neuropathy as well as against different neurodegenerative diseases.
Bibliography:http://dx.doi.org/10.1007/s00018-010-0398-3
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:1420-682X
1420-9071
DOI:10.1007/s00018-010-0398-3